Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025

Rhea-AI Summary

Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company, has scheduled the release of its first quarter 2025 financial results for Monday, May 19, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 AM ET where management will discuss the results and provide a corporate update. Investors can join via phone (U.S.: 1-866-744-5399, International: +972-3-918-0644) or through the company's website. A replay will be available on their website after the live event.

HOLON, Israel, May 5, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its first quarter 2025 financial results on Monday, May 19, 2025, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET.

To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S.,
or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, which is located at the following link. Following the live webcast, a replay will be available on the Company's website.

About Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery platform (Unigen^™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Company contact:

Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071 

View original content:https://www.prnewswire.com/news-releases/compugen-to-release-first-quarter-2025-results-on-monday-may-19-2025-302445841.html

SOURCE Compugen Ltd.

FAQ

When will Compugen (CGEN) release Q1 2025 earnings?

Compugen will release its Q1 2025 earnings on Monday, May 19, 2025, before U.S. market open.

What time is Compugen's Q1 2025 earnings call?

Compugen's Q1 2025 earnings conference call and webcast is scheduled for 8:30 AM ET on May 19, 2025.

How can I join Compugen's Q1 2025 earnings call?

You can join by phone (U.S.: 1-866-744-5399, International: +972-3-918-0644) or through the webcast on Compugen's website.

Will there be a replay of Compugen's Q1 2025 earnings call?

Yes, a replay of the earnings call will be available on Compugen's website following the live webcast.